Diabetes antibody standardization program: First evaluation of assays for autoantibodies to IA-2β

Michael Schlosser, Patricia W. Mueller, Peter Achenbach, Vito Lampasona, Polly J. Bingley

Research output: Contribution to journalArticlepeer-review


OBJECTIVE - Autoantibodies to IA-2β (IA-2βA) are important risk markers of type 1 diabetes. We report the first Diabetes Antibody Standardization Program(DASP) evaluation of IA-2βA assays. RESEARCH DESIGN AND METHODS - Thirteen laboratories from nine countries received coded sera from 50 patients with newly diagnosed type 1 diabetes and 100 healthy blood donors. IA-2βA results were analyzed using receiver operating characteristic (ROC) curves. Concordance of antibody levels was compared using counts per minute (cpm), local and standard curve-derived common units. RESULTS - Median laboratory-assigned sensitivity was 47% (interquartile range [IQR] 45-51), specificity 98% (IQR 95-99), adjusted sensitivity at 95% specificity 50% (IQR 49-53), and area under the ROC curve 0.70 (IQR 0.69-0.73). Use of common IA-2βA units improved concordance between assays compared with local units and cpm (P <0.0001). CONCLUSIONS - IA-2βA assays in multiple laboratories worldwide achieved good concordance and high specificity for type 1 diabetes. IA-2βA are suitable for inclusion in autoantibody testing for risk assessment in prediabetes.

Original languageEnglish
Pages (from-to)2410-2412
Number of pages3
JournalDiabetes Care
Issue number11
Publication statusPublished - Nov 2011

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing


Dive into the research topics of 'Diabetes antibody standardization program: First evaluation of assays for autoantibodies to IA-2β'. Together they form a unique fingerprint.

Cite this